Arie Weber - Purple Biotech Independent Director
KTOV Stock | ILA 24.20 0.10 0.41% |
Director
Mr. Arie Weber serves as Independent Director at Kitov Pharma Ltd since January 22, 2017. He is a Member of Kitov Parent audit, compensation and investment committees. His work experience includes the following roles Chairman of the Board of Scorpio Investments Ltd, Chief Executive Officer of Alonei Meitar Ltd, Chairman of the Board of Inventec Investments Ltd, Manager of the Securities and Investments sector at United Mizrahi Bank, Director at Capital Point Ltd, Lapidoth Israel Oil Prospectors Corporationration Ltd, Sunny Communications Ltd, Mashabim United Mizrahi Bank Offerings Company Ltd, Tel Aviv Stock Exchange Ltd, Maalot Israel Rating Agency and Excellence Investment Management Company and Chairman at Tel Aviv Stock Exchange Clearing House and Bank Mizrahi Registration Company since 2017.
Age | 68 |
Tenure | 7 years |
Phone | 972 3 933 3121 |
Web | http://www.kitovpharma.com |
Purple Biotech Management Efficiency
The company has return on total asset (ROA) of (0.0915) % which means that it has lost $0.0915 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9204) %, meaning that it generated substantial loss on money invested by shareholders. Purple Biotech's management efficiency ratios could be used to measure how well Purple Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Ytzhak Edelman | Bezeq Israeli Telecommunication | 64 | |
Aaron Nahumi | Alony Hetz Properties | 55 | |
Ron Milo | Delek Group | 67 | |
Ilan Biran | Bezeq Israeli Telecommunication | 70 | |
Itshak Forer | Alony Hetz Properties | 80 | |
Binyamin Gabbay | B Communications | 53 | |
Ami Barlev | Bezeq Israeli Telecommunication | 39 | |
Micha Chorin | Discount Investment Corp | 45 | |
Doron Turgeman | Bezeq Israeli Telecommunication | 49 | |
Meir Jacobson | Discount Investment Corp | 64 | |
Gittit Guberman | Alony Hetz Properties | 61 | |
Shimon Doron | Delek Group | 57 | |
Ehud Mezuman | Bezeq Israeli Telecommunication | 62 | |
Efraim Halevy | Azrieli Group | 82 | |
Edith Lusky | Bezeq Israeli Telecommunication | 66 | |
Zeev Vurembrand | Bezeq Israeli Telecommunication | 66 | |
Itzhar Ciechanover | Azrieli Group | 83 | |
Naama Emanuel | Alony Hetz Properties | 33 | |
Elad Zadok | Discount Investment Corp | 35 | |
Avraham Harel | Delek Group | 70 | |
Amikam Shorer | Bezeq Israeli Telecommunication | 49 |
Management Performance
Return On Equity | -0.92 | |||
Return On Asset | -0.0915 |
Purple Biotech Leadership Team
Elected by the shareholders, the Purple Biotech's board of directors comprises two types of representatives: Purple Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Purple. The board's role is to monitor Purple Biotech's management team and ensure that shareholders' interests are well served. Purple Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Purple Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Itzhak Israel, Chief Executive Officer & Director | ||
Steven Steinberg, Independent Director | ||
Gil BenMenachem, Vice President - Business Development | ||
Michael Schickler, Head of Clinical Operations | ||
Philip Serlin, Independent Director | ||
CPA MBA, Strategic Director | ||
Arie Weber, Independent Director | ||
Bertrand Liang, Chief Medical Officer | ||
Yisrael Gewirtz, Internal Auditor | ||
John Waymack, Chairman of the Board & Chief Medical Officer | ||
Ran Tzror, Independent Director | ||
Gil Efron, Deputy Chief Executive Officer, Chief Financial Officer | ||
Simcha Rock, CFO, Director | ||
Eric Rowinsky, Chairman of the Board | ||
Moran SherfBlau, External Director | ||
Ido Agmon, Independent Director | ||
Gil CPA, Deputy CFO | ||
Leah Bruck, Director | ||
Isaac Israel, CEO Director | ||
Revital SternRaff, Independent Director | ||
Pinhas BarShmuel, Internal Auditor | ||
Avraham BenTzvi, General Counsel, Secretary | ||
Alain Zeitoun, External Director | ||
Hadas Reuveni, Founder and Chief Technology Officer of TyrNovo (a subsidiary) |
Purple Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Purple Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.92 | |||
Return On Asset | -0.0915 | |||
Operating Margin | (7.54) % | |||
Shares Outstanding | 172.11 M | |||
Shares Owned By Insiders | 0.12 % | |||
Shares Owned By Institutions | 1.22 % | |||
Price To Earning | (364.21) X | |||
Price To Book | 1.27 X | |||
Price To Sales | 16.36 X | |||
Revenue | 1000 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Purple Stock refer to our How to Trade Purple Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Purple Stock analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Global Correlations Find global opportunities by holding instruments from different markets |